3 active not recruiting, 3 recruiting, 2 completed, 1 suspended. 3 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow Malignant Uterine Neoplasm: new trials by email Literature Review of Malignant Uterine Neoplasm trials Research Report on Malignant Uterine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers Best Practice, Cilostazol, Cryocompression Therapy - Cervical Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Emory University | 70 | 2024-08-01 | 2026-08-27 |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer Biopsy, Cisplatin, Doxorubicin - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 49 | 2020-08-21 | 2026-08-26 |
| Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors Questionnaire Administration - Endometrial Carcinoma, Malignant Uterine Neoplasm | Active not recruiting | M.D. Anderson Cancer Center | 310 | 2020-01-09 | 2026-05-20 | |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey - Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer | Suspended | Wake Forest University Health Sciences | 55 | 2019-11-11 | 2026-08-13 | |
| Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers Biospecimen Collection, Liquid Biopsy, Pap Smear - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Recruiting | M.D. Anderson Cancer Center | 1000 | 2019-06-18 | 2026-10-07 | |
| Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study Explantation, Quality-of-Life Assessment, Questionnaire Administration - Low Anterior Resection Syndrome, Malignant Anal Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-04-12 | 2023-08-14 |
| EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery Questionnaire Administration, Supportive Care - Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm | Not applicable | Completed | Wake Forest University Health Sciences | 10 | 2018-04-05 | 2019-12-30 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma | Early Phase 1 | Completed | Mayo Clinic | 2 | 2016-01-01 | 2019-06-06 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
Uterine Neoplasms (10) · Ovarian Neoplasms (8) · Uterine Cervical Neoplasms (6) · Breast Neoplasms (4) · Prostatic Neoplasms (4) · Urinary Bladder Neoplasms (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Lung Neoplasms (3) · Stomach Neoplasms (3) · Vulvar Neoplasms (3) · Anus Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Neoplasms (10) · Neoplasms by Site (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Uterine Diseases (10) · Genital Neoplasms, Female (9) · Adnexal Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Gonadal Disorders (8) · Ovarian Diseases (8)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Blood Specimen Collection (1) · CT-P6 (1) · Cilostazol (1) · Cisplatin (1) · Crizotinib (1) · Dasatinib (1) · Device Removal (1)
M.D. Anderson Cancer Center (3) · Wake Forest University Health Sciences (2) · City of Hope Medical Center (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (10) · Guam (1) · Puerto Rico (1)
Craig A Messick, MD (1) · Jeremie Calais (1) · Keith T Flaherty (1) · Lilie L Lin (1) · Mitesh Borad (1) · Mustafa Raoof, MD (1) · Pamela T Soliman (1) · Roy Strowd, MD (1) · Stephanie Sohl (1) · Susan C Modesitt (1) · Thanh H Dellinger, MD (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
P30CA012197 (2), P30CA015083 (1), P30CA033572 (1), P30CA138292 (1), U10CA180820 (1), U24CA196172 (1)